Stockreport

Biond Biologics Announces First Patient Dosed with BND-35 in Phase 1 Clinical Trial [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF BND-35 -001 trial includes unique combination arms with anti-EGFR (cetuximab) and anti-PD-1/PD-L1, in selected indications MISGAV, Israel June 24, 2024 /PRNewswire/ - [Read more]